A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Ceritinib (Primary) ; Ribociclib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2017 Planned End Date changed from 1 Oct 2018 to 18 Oct 2018.
- 23 Feb 2017 Planned primary completion date changed from 1 Oct 2018 to 18 Oct 2018.